edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
In this interview with Petter Segelman Lindqvist, CEO of Isofol Medical, we discuss the company’s lead clinical programme, the mechanism of action of arfolitixorin and the recently announced rights issue. We also highlight the key catalysts that investors should watch out for in the year ahead.
Isofol Medical is a Sweden-based clinical-stage biotechnology company dedicated to improving prognoses for patients with severe forms of cancer. The company’s lead clinical candidate, arfolitixorin, is designed to increase the effect of standard treatments for several forms of solid tumours, with an initial focus on colorectal cancer. A Phase Ib/II trial is currently underway, following first patient dosing in April 2025.
Get access to the very latest content matched to your personal investment style.